Fierce BioTech

AUGUST 14, 2024

Epilepsy Clinical Trials Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.

Clinical Trials 52

Clinical Trials Trials Therapies Treatment 52

PPD

DECEMBER 16, 2024

Internal costs: The complexity of protocol designs a necessity for innovative therapies often requires more diverse patient populations, more extensive data collection and sophisticated trial methodologies, all of which demand higher financial outlays. Nearly 39% of sponsors cite these costs as primarily driven by complex protocols.

Drug Development 52

Drug Development Compliance Clinical Trials Trials 52

The Pharma Data

NOVEMBER 1, 2020

Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company. Maryland , US), a leading gene therapy company. PARIS , Nov.

Therapies 52

Therapies Science Treatment Disease 52

The Pharma Data

JANUARY 27, 2021

HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). View original content to download multimedia: [link]. CAMBRIDGE, Mass.

Therapies 40

Therapies Treatment International Licensing 40

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

The Pharma Data

JANUARY 12, 2021

a biopharmaceutical company focused on the development of first-in-class therapeutics for the treatment of cancer, today announced the completion of the Phase 1b clinical trial conducted by the NCI with its lead clinical candidate zotiraciclib (ZTR/TG02), a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor. .

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

Fierce BioTech

JULY 25, 2023

How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.

Pharma Companies 52

Pharma Companies Government Therapies Disease 52

Fierce BioTech

NOVEMBER 16, 2023

Beyond cfDNA: Harnessing the Power of Exosomes to Improve Sensitivity for Cancer Mutation Detection Liquid biopsy markers are advantageous because they can be used to assess overall prognosis, response to therapy, and likelihood of relapse or progression. Download now. Download now.

RNA 52

RNA DNA Therapies Treatment 52

The Pharma Data

JANUARY 17, 2021

a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2a clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. GAITHERSBURG, Md.

Treatment 52

Treatment Trials FDA Approval RNA 52

PPD

SEPTEMBER 25, 2023

Historically, clinical trial populations were almost exclusively comprised of white, male participants,  exacerbating gaps in knowledge of diseases and conditions , preventive factors and treatment effectiveness. DOWNLOAD THE FULL REPORT The post New Report Reveals Trends, Opportunities in Drug Development appeared first on PPD Inc.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

The Pharma Data

NOVEMBER 23, 2020

CMTI) has received 60+ red light therapy (RLT) modules for initial photonics testing and product fabrication. View original content to download multimedia: [link]. FRISCO, Texas , Nov. 24, 2020 /PRNewswire/ — Curtis Mathes Corporation (OTC: TLED) subsidiary, Curtis Mathes Therapeutics, Inc.

Therapies 40

Therapies Treatment Production Research 40

The Pharma Data

SEPTEMBER 15, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. Balance risk and innovation in regulation using new digital-therapy products.

Regulations 52

Regulations Production Therapies Treatment 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. View original content to download multimedia: [link]. SOURCE Eli Lilly and Company.

Therapies 52

Therapies Production Government Disease 52

The Pharma Data

JANUARY 9, 2021

(NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.

Therapies 52

Therapies Trials Clinical Trials Treatment 52

The Pharma Data

NOVEMBER 26, 2020

Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for review of the Company’s Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease. About Pegunigalsidase Alfa.

Disease 52

Disease Treatment Clinical Trials FDA 52

The Pharma Data

JANUARY 7, 2021

– January 8, 2021) – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is participating in Biotech Showcase 2021 and will be presenting the strategic plan for long-term growth. Foster City, California–(Newsfile Corp.

Pharmaceutical Companies 52

Pharmaceutical Companies Therapies Science Pharmaceuticals 52

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — Nevro Corp (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ?65% . REDWOOD CITY, Calif. , .

Therapies 52

Therapies Treatment Production 52

The Pharma Data

JANUARY 13, 2021

Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. WAKEFIELD, Mass.,

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. Cantargia AB (publ), reg.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

JANUARY 31, 2021

The practice offers standard and advanced therapeutics including chemotherapy, biologic therapy immunotherapies and radiopharmaceuticals along with a total complement of radiation oncology treatment options, including proton therapy, brachytherapy, and radiosurgery. View original content to download multimedia: [link].

Clinical Trials 52

Clinical Trials Therapies Trials Treatment 52

PPD

OCTOBER 12, 2023

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

The Pharma Data

NOVEMBER 4, 2020

4, 2020 /PRNewswire/ — Gracell Biotechnologies Inc. (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced two oral presentations at the 62 nd ASH Annual Meeting and Exposition in December.

Therapies 40

Therapies Treatment Production 40

The Pharma Data

DECEMBER 2, 2020

Abemaciclib is a cyclin dependent kinase (CDK) 4 & 6 inhibitor used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. View original content to download multimedia: [link]. . PLYMOUTH MEETING, Pa. , .

Research 52

Research Treatment Therapies Clinical Research 52

The Pharma Data

DECEMBER 9, 2020

The targeted indication is for treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The following files are available for download: View original content: [link].

FDA Approval 40

FDA Approval Therapies FDA Treatment 40

The Pharma Data

OCTOBER 20, 2020

About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The following files are available for download: View original content: [link]. The information was submitted for publication at 08.30 CET on October 21, 2020. Source link.

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment FDA Therapies 52

The Pharma Data

JANUARY 22, 2021

Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ Lupkynis TM (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis (LN) in combination with standard of care. [1] Lupus and Kidney Disease (Lupus Nephritis).

Research 52

Research Treatment FDA Approval Disease 52

The Pharma Data

JANUARY 26, 2021

The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. View original content to download multimedia: [link].

Therapies 52

Therapies Treatment Drugs Disease 52

The Pharma Data

OCTOBER 14, 2020

“We look forward to continuing to advance apraglutide and to preparing our organization to bring a potential best-in-class therapy to people living with SBS.” and Europe , of whom 15,000 require lifelong PS and may thus be candidates for treatment with GLP-2 analogs. View original content to download multimedia: [link].

Disease 52

Disease Treatment Therapies Production 52

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients. About ImaginAb. ImaginAb Inc. Source link.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JANUARY 27, 2021

. “The responses observed in six out of nine patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives. Subjects in each phase receive 1 cycle (4 doses) of induction therapy with BI-1206 in combination with rituximab.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

KIF1A

AUGUST 28, 2024

KIF1A.ORG’s Chief Science Officer Dr. Dylan Verden will provide an overview of current areas of KAND therapeutic… Tuesday, September 24, 2024 5:00 pm – 6:00 pm Online via Zoom [link] ASO therapy: Positive Clinical Outcomes Observed We are thrilled to announce the publication of the **first-ever KAND ASO study** !

Therapies 52

Therapies Compound Screening Research Treatment 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — UNION therapeutics A/S ( UNION ) today announces that the US Food and Drug Administration (FDA) has approved an Investigational New Drug program (IND) for oral orismilast; a next generation PDE4-inhibitor for the treatment of plaque psoriasis in adults. One step closer to a novel treatment. Source link.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

OCTOBER 16, 2020

Novan has been evaluating the ability of its NITRICIL platform technology as a potential nasal treatment option for Covid-19, announcing its potential efficacy as an antiviral against SARS-CoV-2, the virus that causes Covid-19. In vitro antiviral technology proves effective against SARS-CoV-2 in human airway infection model. Source link.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

JANUARY 13, 2021

Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA. View original content to download multimedia: [link]. . NEW YORK , Jan. MindMed Co-CEO J.R.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

JANUARY 23, 2021

On a larger scale, the tool may greatly aid existing and future TNBC studies that are currently exploring new therapies for targeted treatments. TNBC is an incredibly challenging and aggressive form of breast cancer compared to other subtypes and holds a relatively poor prognosis primarily due to a lack of targeted treatments.

Treatment 52

Treatment Cell Biology Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

The global GBM treatment market is projected to reach $3.3 The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist.

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52

The Pharma Data

OCTOBER 19, 2020

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. IRVING, Texas and ATLANTA , Oct. Winship is one of 32 U.S. Ramalingam , M.D.,

Clinical Trials 52

Clinical Trials RNA DNA Science 52